LINDSAY KAUFMAN: Open Payments
NPI 1225502859 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$164 in 9 payments from 8 companies in 2025. Trend: 2023 $692 · 2024 $1,040 · 2025 $164
Food & beverage: $164
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| Novo Nordisk Inc | 1 | $24 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 1 | $20 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Edwards Lifesciences Corporation | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Merck Sharp & Dohme LLC | 1 | $14 |
Products named: FARXIGA, Ozempic, LifeVest, Kerendia, EVKEEZA, SAPIEN 3 Ultra RESILIA, ONPATTRO, VERQUVO.
Industry payments across IN — which companies pay providers there.
